表紙
市場調查報告書
商品編碼
926047

In Silico/電腦支援創藥服務全球市場:抗體、蛋白質、勝□、核酸、基因治療、載體(2020年∼2030年)

In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug

出版日期: | 出版商: Roots Analysis | 英文 328 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

概要

使用In Silico服務可以節省30%以上的投資於新藥開發的總費用。然而,其變動非常大,仰賴著創藥專案的性質。從藥理學上發現先導化合物到商業販售,醫藥品開發的流程大約40億到100億美元的設備投資資金,開發期間也約長達10年到15年。此外,眾所皆知,在研究初期階段被選中的先導化合物僅有一小部分會實際成為臨床調查研究的候補藥物。隨著時間經過,創藥的複雜性也增加。這在高分子醫藥品當中比傳統低分子醫藥品更常見。其結果,製藥/生物科技部門的研究開發支出也隨之增加。具體來說,報告指出,2019年的全球創藥研究開發支出推測約為1,820億美元,有超過16,000件藥物分子受到研究。

本報告調查了全球In Silico/電腦支援創藥服務市場,並提供In Silico創藥概要、現今市場狀況、高分子治療藥的創藥專案數、創藥當中採用In Silico服務的情形、外包檔案、創藥階段(鎖定目標、驗證目標、生成活性化合物、活性化合物至先導化合物、先導化合物最佳化)、高分子類型(抗體、蛋白質、勝□、核酸、載體)、企業規模(小規模、中規模、大規模)、治療領域(自體免疫疾病、血液疾病、心血管疾病、消化器疾病等)、客戶類型(製藥/生技企業、學術/研究機構)、地區別機會分析與預測、預測規劃、主要企業檔案等體系化資訊。

目次

第1章 簡介

  • 研究範圍
  • 研究方法
  • 各章概要

第2章 執行摘要

第3章 簡介

  • 概述
  • 創藥與開發的時間表
  • In Silico創藥工具的概要
  • In Silico工具在創藥流程中的用途
    • 標的辨認
    • 標的驗證
    • 活性化合物世代
    • 活性化合物到先導化合物
    • 先導化合物最佳化
  • 於創藥使用In Silico工具的優點
  • 進行In Silico創藥業務所伴隨的挑戰
  • 預期在In Silico創藥業務的外包將會增加
  • 結語

第4章 市場情勢

  • 概述
  • 高分子In Silico創藥服務:企業一覽
  • In Silico創藥服務:軟體、技術一覽
  • In Silico創藥服務:諮詢顧問、訓練服務業者一覽

第5章 主要發現

  • 概述
  • 企業規模與總公司所在地
  • 企業規模與創藥階段的分析
  • 外包活動的地區分析
  • 高分子類型、受到使用的In Silico途徑、客戶類型

第6章 企業檔案

  • 概述
  • 北美主要企業
    • BioDuro
    • Creative Biostructure
    • GenScript
    • LakePharma
  • 歐洲主要企業
    • Abzena
    • BioNTech
    • Sygnature Discovery
  • 亞太地區主要企業
    • ChemPartner
    • Sundia MediTech
    • Viva Biotech

第7章 競爭分析

  • 概述
  • 主要前提條件與研究方法
  • 企業競爭力分析:北美In Silico創藥服務業者
  • 企業競爭力分析:歐洲In Silico創藥服務業者
  • 企業競爭力分析:亞太地區、其他地區In Silico創藥服務業者

第8章 主要機會領域

  • 概述
  • 主要前提條件與研究方法
  • 抗體
  • 細胞療法
  • 基因治療
  • 核酸
  • 勝□
  • 蛋白質
  • 載體

第9章 新的商業模式與策略

  • 概述
  • 主要前提條件與研究方法
  • In Silico服務業者
    • 短期的成功策略
    • 長期的成功策略
  • 總論

第10章 案例研究:低分子醫藥品、高分子醫藥品創藥流程的比較

  • 概述
  • 低分子醫藥品、高分子醫藥品
  • 高分子醫藥品創藥流程的改善途徑

第11章 調查分析

  • 概述
  • 回答者概要
  • 調查發現
    • 創藥階段
    • 高分子醫藥品種類
    • In Silico服務投資組合
    • 在高分子醫藥品創藥使用In Silico工具的可能性
    • 現在的市場機會
    • 以In Silico方式降低成本的可能性

第12章 成本降低分析

  • 概述
  • 重要假設
  • 範圍與調查手法
  • 在高分子醫藥品創藥中使用In Silico工具降低整體成本的可能性
  • 總論

第13章 市場預測

  • 概述
  • 調查方法與主要假設
  • 高分子醫藥品的In Silico創藥服務市場
    • 創藥階段別
    • 高分子類型別
    • 企業規模別
    • 治療領域別
    • 贊助商別
    • 地區別

第14章 In Silico工具與未來趨勢

  • 概述
  • 透過潛在成本與時間相關優點,預測未來將增加創藥業務外包
  • 技術進步有很高的可能會為現今的創藥流程帶來革命
  • 總論

第15章 高等研究

  • 概述
  • ProSciens
  • Conifer Point Pharmaceuticals
  • Evotec
  • Candidum

第16章 附錄I

第17章 附錄II

第18章 附錄III

目錄

Title:
In Silico / Computer-Aided Drug Discovery Services Market:
Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches).

Example Insights:

Featuring the presence of small-mid sized firms, the ‘in silico’ service provider landscape is well-distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients.

Overview:

"Over 30% of the total cost invested in developing a new drug can be saved by utilizing in silico services. However, this is highly variable and is dependent upon the nature of drug discovery projects." -- CEO, a US-based small-sized company.

The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector. Specifically, in 2019, the global R&D spending was estimated to be around USD 182 billion, with over 16,000 drug molecules reported to have been investigated. Presently, the industry is currently under tremendous pressure to identify ways to cope with rising capital requirements in drug discovery research and actively avoid losses owing to failed drug development programs. In addition, there has been an evident increase in regulatory stringency, which has made the drug approval process, especially for large molecules, significantly more difficult.

Scope of the Report:

The “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)” report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders. In addition to other elements, the report includes:

  • A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
  • Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
  • Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
  • A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
  • An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
  • A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
  • A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
  • An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
  • A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
  • A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
  • A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.

One of the key objectives of this report was to understand the primary growth drivers and estimate the future size of the in silico drug discovery services market. Based on several parameters, such as number of large molecules based drug discovery projects, adoption of in silico services for drug discovery and outsourcing profile, we have provided informed estimates on the likely evolution of the market for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors), [C] company size (small, mid-sized and large), [D] therapeutic area (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others), [E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), and [F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe) and Asia-Pacific (China, India and Japan), along with the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this report were also influenced by inputs solicited via a survey and discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following individuals (in alphabetical order):

  • John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point)
  • Sven Benson (Founder, candidum)
  • Mark Whittaker (Senior Vice President, Evotec)
  • Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the in silico services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides an introduction to the overall drug discovery process, including details on the time taken for a drug to traverse from the bench to the market, and the various stages of the drug discovery process. It also provides an overview of various in silico drug discovery approaches, and a detailed classification of computer-aided research tools and techniques. In addition, it features information on the applications of in silico tools across different steps of the drug discovery process, along with details of specific in silico methods / approaches associated with these steps. It also highlights the benefits of the in silico approach and the key challenges associated with carrying out in silico (including CADD) drug discovery research in-house. Finally, the chapter highlights the current preference to outsource such operations, especially for large molecule drugs.

Chapter 4 provides an assessment of the global landscape of the in silico services market. It includes information on over 60 players that are currently engaged in providing such services for discovery of large molecules. It features an in-depth market overview, including information on location of headquarters, employee count, type of business model used (contract service providers, software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, ADCs, antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors, nucleic acids), type of in silico approach used (SBDD, FBDD, TBDD, LBDD and IBDD), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes). It also includes the list of various software tools / web applications / technology platforms offered by the in silico service providers for the drug discovery, has been provided.

Chapter 5 presents a compilation of the key insights generated from the study highlighting the contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of the location of their company size (small-sized (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.

Chapter 6 features detailed profiles of key industry in silico drug discovery service providers, which were established after 2000 and have an employee base of more than 500 individuals. Each profile provides an overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio, and an informed future outlook. In addition, each profile features a peer group-based benchmark comparison matrix for the players based on several parameters, such as experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.

Chapter 7 features an insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services and number of large molecules for which the aforementioned services are offered.

Chapter 8 presents the detailed analysis assessing the current opportunity within in silico drug discovery services market, along with the comparison of the number of pipeline products and current market size across different types of large molecules and the availability and capabilities of affiliated in silico drug discovery service providers.

Chapter 9 features the various business strategies that can be adopted by in silico service providers for maintaining the competitive edge in the industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.

Chapter 10 presents the comparison of the challenges associated with the discovery and production of large molecules, comparing affiliated product development timelines, and manufacturing protocols with those of small molecule drugs. In addition, several approaches have been highlighted, which can be incorporated to overcome the challenges in the drug discovery of large molecules.

Chapter 11 presents insights generated from an industry-wide survey, wherein we had approached nearly 100 stakeholders involved in outsourcing in silico services. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 12 presents a comprehensive analysis of the cost saving potential associated with the use of in silico services in the drug discovery process for large molecules.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of the in silico drug discovery services market till the year 2030. It features the likely distribution of the market based on [A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors), [C] company size (small-sized, mid-sized and large), [D] therapeutic areas (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others), [E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), and [F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe), and Asia-Pacific (China, India and Japan), along with the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 14 provides a brief overview of the upcoming computational technologies, which are being developed to deal with the innate complexities associated with the process of drug discovery and optimize the overall time spent on early stage research.

Chapter 15 is a collection of interview transcripts of discussions held with key stakeholders in this industry. In this chapter, we have presented the details of our conversations held with John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals), Sven Benson (Founder, candidum), Mark Whittaker (Senior Vice President, Evotec) and Edelmiro Moman (Scientific Consultant and Teacher, ProSciens).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

Chapter 18 is an appendix, which features a detailed discussion of several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Drug Discovery and Development Timelines
  • 3.3. Overview of In Silico Drug Discovery Tools
    • 3.3.1. Historical Evolution of the In Silico Approach
    • 3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
    • 3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development
  • 3.4. Applications of In Silico Tools in the Drug Discovery Process
    • 3.4.1. Target Identification
      • 3.4.1.1. Chemoinformatics-based Tools
      • 3.4.1.2. Network-based Drug Discovery
      • 3.4.1.3. Computational Platforms and Interaction Repositories
    • 3.4.2. Target Validation
    • 3.4.3. Hit Generation
      • 3.4.3.1. High-Throughput Screening
      • 3.4.3.2. Fragment Based Screening
      • 3.4.3.3. Virtual Screening
    • 3.4.4. Hit-to-Lead
      • 3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
      • 3.4.4.2. Other Novel Approaches
    • 3.4.5. Lead Optimization
      • 3.4.5.1. Pharmacophore Modeling
      • 3.4.5.2. Docking
      • 3.4.5.3. Structure Activity Relationships(SAR) / Quantitative Structure Activity Relationship(QSAR)
      • 3.4.5.4. Molecular Modeling
  • 3.5. Advantages of using In Silico Tools for Drug Discovery
  • 3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations
  • 3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
  • 3.8. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Company Size and Location of Headquarters
    • 4.2.5. Analysis by Type of Business Model
    • 4.2.6. Analysis by Drug Discovery Steps
    • 4.2.7. Analysis by Type of Large Molecule
      • 4.2.7.1. Analysis by Type of Antibody
      • 4.2.7.2. Analysis by Type of Protein
    • 4.2.8. Analysis by Type of In Silico Approach Used
    • 4.2.9. Analysis by Types of In Silico Services Offered
    • 4.2.10. Analysis by Type of Clientele
  • 4.3. In Silico Drug Discovery Services: List of Software / Technologies
  • 4.4. In Silico Drug Discovery Services: List of Consulting and Training Service Providers

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
  • 5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
  • 5.4. World Map Representation: Regional Analysis of Outsourcing Activity
  • 5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Leading Players Based in North America
    • 6.2.1. BioDuro
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Funding and Investment Information
      • 6.2.1.3. In Silico-based Service Portfolio
      • 6.2.1.4. Recent Developments and Future Outlook
      • 6.2.1.5. Company Benchmarking Output
    • 6.2.2. Creative Biostructure
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Funding and Investment Information
      • 6.2.2.3. In Silico-based Service Portfolio
      • 6.2.2.4. Recent Developments and Future Outlook
      • 6.2.2.5. Company Benchmarking Output
    • 6.2.3. GenScript
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Funding and Investment Information
      • 6.2.3.3. In Silico-based Service Portfolio
      • 6.2.3.4. Recent Developments and Future Outlook
      • 6.2.3.5. Company Benchmarking Output
    • 6.2.4. LakePharma
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Funding and Investment Information
      • 6.2.4.3. In Silico-based Service Portfolio
      • 6.2.4.4. Recent Developments and Future Outlook
      • 6.2.4.5. Company Benchmarking Output
  • 6.3. Leading Players Based in Europe
    • 6.3.1. Abzena
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Funding and Investment Information
      • 6.3.1.3. In Silico-based Service Portfolio
      • 6.3.1.4. Recent Developments and Future Outlook
      • 6.3.1.5. Company Benchmarking Output
    • 6.3.2. BioNTech
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Funding and Investment Information
      • 6.3.2.3. In Silico-based Service Portfolio
      • 6.3.2.4. Recent Developments and Future Outlook
      • 6.3.2.5. Company Benchmarking Output
    • 6.3.3. Sygnature Discovery
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Funding and Investment Information
      • 6.3.3.3. In Silico-based Service Portfolio
      • 6.3.3.4. Recent Developments and Future Outlook
      • 6.3.3.5. Company Benchmarking Output
  • 6.4. Leading Players Based in Asia-Pacific
    • 6.4.1. ChemPartner
      • 6.4.1.1. Company Overview
      • 6.4.1.2. In Silico-based Service Portfolio
      • 6.4.1.3. Recent Developments and Future Outlook
      • 6.4.1.4. Company Benchmarking Output
    • 6.4.2. Sundia MediTech
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Funding and Investment Information
      • 6.4.2.3. In Silico-based Service Portfolio
      • 6.4.2.4. Recent Development and Future Outlook
      • 6.4.2.5. Company Benchmarking Output
    • 6.4.3. Viva Biotech
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Funding and Investment Information
      • 6.4.3.3. In Silico-based Service Portfolio
      • 6.4.3.4. Recent Development and Future Outlook
      • 6.4.3.5. Company Benchmarking Output

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Key Assumptions and Methodology
  • 7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
  • 7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
  • 7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World

8. KEY OPPORTUNITY AREAS

  • 8.1. Chapter Overview
  • 8.2. Key Assumptions and Methodology
  • 8.3. Antibodies
    • 8.3.1. Developer Landscape
      • 8.3.1.1. Number of Pipeline Molecules
      • 8.3.1.2. Affiliated Market Size and Growth Rate
    • 8.3.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.4. Cell Therapies
    • 8.4.1. Developer Landscape
      • 8.4.1.1. Number of Pipeline Molecules
      • 8.4.1.2. Affiliated Market Size and Growth Rate
    • 8.4.2. In Silico Service Providers for Cell Therapies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.5. Gene Therapies
    • 8.5.1. Developer Landscape
      • 8.5.1.1. Number of Pipeline Molecules
      • 8.5.1.2. Affiliated Market Size and Growth Rate
    • 8.5.2. In Silico Service Providers for Gene Therapies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.6. Nucleic Acids
    • 8.6.1. Developer Landscape
      • 8.6.1.1. Number of Pipeline Molecules
      • 8.6.1.2. Affiliated Market Size and Growth Rate
    • 8.6.2. In Silico Service Providers for Nucleic Acids: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.7. Peptides
    • 8.7.1. Developer Landscape
      • 8.7.1.1. Number of Pipeline Molecules
      • 8.7.1.2. Affiliated Market Size and Growth Rate
    • 8.7.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.8. Proteins
    • 8.8.1. Developer Landscape
      • 8.8.1.1. Number of Pipeline Molecules
      • 8.8.1.2. Affiliated Market Size and Growth Rate
    • 8.8.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.9. Vectors
    • 8.9.1. Developer Landscape
      • 8.9.1.1. Number of Pipeline Molecules
      • 8.9.1.2. Affiliated Market Size and Growth Rate
    • 8.9.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

9. EMERGING BUSINESS MODELS AND STRATEGIES

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
    • 9.3.1. Strategies for Short Term Success
    • 9.3.2. Strategies for Long Term Success
  • 9.4. Concluding Remarks

10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES

  • 10.1. Chapter Overview
  • 10.2. Small Molecule and Large Molecule Drugs
    • 10.2.1. Comparison of Key Specifications
    • 10.2.2. Comparison of Manufacturing Processes
    • 10.2.3. Comparison of Drug Discovery Processes
  • 10.3. Approaches to Improve Discovery Process of Large Molecules

11. SURVEY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Overview of Respondents
    • 11.2.1. Seniority Level of Respondents
  • 11.3. Survey Insights
    • 11.3.1. Drug Discovery Steps
    • 11.3.2. Type of Large Molecules
    • 11.3.3. In Silico Service Portfolio
    • 11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
    • 11.3.5. Current Market Opportunity
    • 11.3.6. Cost Saving Potential of the In Silico Approach

12. COST SAVING ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions
  • 12.3. Scope and Methodology
  • 12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030
  • 12.5. Concluding Remarks

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030
    • 13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020-2030
      • 13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, 2020-2030
      • 13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, 2020-2030
      • 13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, 2020-2030
      • 13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, 2020-2030
      • 13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, 2020-2030
    • 13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020-2030
      • 13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, 2020-2030
      • 13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, 2020-2030
      • 13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, 2020-2030
      • 13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, 2020-2030
      • 13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, 2020-2030
    • 13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020-2030
      • 13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, 2020-2030
      • 13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, 2020-2030
      • 13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, 2020-2030
    • 13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, 2020-2030
      • 13.3.4.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, 2020-2030
      • 13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, 2020-2030
      • 13.3.4.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, 2020-2030
      • 13.3.4.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, 2020-2030
      • 13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, 2020-2030
      • 13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus(HIV) / Acquired Immunodeficiency Syndrome(AIDS), 2020-2030
      • 13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, 2020-2030
      • 13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, 2020-2030
      • 13.3.4.9. In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, 2020-2030
      • 13.3.4.10. In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, 2020-2030
      • 13.3.4.11. In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, 2020-2030
      • 13.3.4.12. In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders 2020-2030
      • 13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, 2020-2030
      • 13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, 2020-2030
      • 13.3.4.14. In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, 2020-2030
      • 13.3.4.15. In Silico Drug Discovery Services Market for Large Molecules: Share of Others, 2020-2030
    • 13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020-2030
      • 13.3.5.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, 2020-2030
      • 13.3.5.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, 2020-2030
    • 13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020-2030
      • 13.3.6.1. In Silico Drug Discovery Services Market for Large Molecules: Share of North America, 2020-2030
        • 13.3.6.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of US, 2020-2030
        • 13.3.6.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, 2020-2030
      • 13.3.6.2. In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, 2020-2030
        • 13.3.6.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, 2020-2030
        • 13.3.6.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share in France, 2020-2030
        • 13.3.6.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, 2020-2030
        • 13.3.6.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, 2020-2030
        • 13.3.6.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, 2020-2030
        • 13.3.6.2.6. In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, 2020-2030
      • 13.3.6.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, 2020-2030
        • 13.3.6.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share in China, 2020-2030
        • 13.3.6.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share in India, 2020-2030
        • 13.3.6.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, 2020-2030

14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY

  • 14.1. Chapter Overview
  • 14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
  • 14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
    • 14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve the Overall Efficiency and Productivity
    • 14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
    • 14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
  • 14.4. Concluding Remarks

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. ProSciens
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer
  • 15.3. Conifer Point Pharmaceuticals
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer
  • 15.4. Evotec
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery
  • 15.5. Candidum
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Sven Benson, Founder

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

List Of Figures

  • Figure 3.1. Drug Discovery and Development Timeline
  • Figure 3.2. Historical Evolution of Computational Drug Discovery Approaches
  • Figure 3.3. Steps Involved in the Virtual Drug Discovery Process
  • Figure 3.4. Comparison of Traditional and In Silico Drug Discovery Approaches
  • Figure 3.5. Classification of In Silico Drug Discovery Approaches
  • Figure 3.6. Flowchart of the In Silico Drug Discovery Approach
  • Figure 3.7. In Silico Drug Discovery Service Map
  • Figure 3.8. Advantages of using In Silico Drug Discovery Services
  • Figure 3.9. Types of Large Molecule Drugs
  • Figure 4.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
  • Figure 4.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
  • Figure 4.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
  • Figure 4.4. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
  • Figure 4.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
  • Figure 4.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
  • Figure 4.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
  • Figure 4.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
  • Figure 4.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of In Silico Approach Used
  • Figure 4.10. In Silico Drug Discovery Services for Large Molecules: Distribution by Types of In Silico Services Offered
  • Figure 5.1. Logo Landscape: Distribution by Company Size and Location of Headquarters
  • Figure 5.2. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
  • Figure 5.3. World Map Representation: Regional Analysis of Outsourcing Activity
  • Figure 5.4. Grid Representation: Distribution by Type of Large Molecule, Designing Approach Used and Type of Clientele
  • Figure 6.1. BioDuro: In Silico-based Service Portfolio
  • Figure 6.2. BioDuro: Peer Group Benchmark Comparison
  • Figure 6.3. Creative Biostructure: In Silico-based Service Portfolio
  • Figure 6.4. Creative Biostructure: Peer Group Benchmark Comparison
  • Figure 6.5. GenScript: In Silico-based Service Portfolio
  • Figure 6.6. GenScript: Peer Group Benchmark Comparison
  • Figure 6.7. LakePharma: In Silico-based Service Portfolio
  • Figure 6.8. LakePharma: Peer Group Benchmark Comparison
  • Figure 6.9. Abzena: In Silico-based Service Portfolio
  • Figure 6.10. Abzena: Company Benchmarking Output
  • Figure 6.11. BioNTech: In Silico-based Service Portfolio
  • Figure 6.12. BioNTech: Peer Group Benchmark Comparison
  • Figure 6.13. Sygnature Discovery: In Silico-based Service Portfolio
  • Figure 6.14. Sygnature Discovery: Peer Group Benchmark Comparison
  • Figure 6.15. ChemPartner: In Silico-based Service Portfolio
  • Figure 6.16. ChemPartner: Peer Group Benchmark Comparison
  • Figure 6.17. Sundia MediTech: In Silico-based Service Portfolio
  • Figure 6.18. Sundia MediTech: Peer Group Benchmark Comparison
  • Figure 6.19. Viva Biotech: In Silico-based Service Portfolio
  • Figure 6.20. Viva Biotech: Peer Group Benchmark Comparison
  • Figure 7.1. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
  • Figure 7.2. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
  • Figure 7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
  • Figure 8.1. In Silico Drug Discovery Service Providers for Antibodies: 3D Bubble Representation
  • Figure 8.2. In Silico Drug Discovery Service Providers for Cell Therapies: 3D Bubble Representation
  • Figure 8.3. In Silico Drug Discovery Service Providers for Gene Therapies: 3D Bubble Representation
  • Figure 8.4. In Silico Drug Discovery Service Providers for Nucleic Acids: 3D Bubble Representation
  • Figure 8.5. In Silico Drug Discovery Service Providers for Peptides: 3D Bubble Representation
  • Figure 8.6. In Silico Drug Discovery Service Providers for Proteins: 3D Bubble Representation
  • Figure 8.7. In Silico Drug Discovery Service Providers for Vectors 3D Bubble Representation
  • Figure 9.1. In Silico Drug Discovery Service Providers: Popular Strategies or Business Models
  • Figure 10.1. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005-2019)
  • Figure 10.2. Small Molecules versus Large Molecules: Comparison of Key Characteristics
  • Figure 10.3. Small Molecules versus Large Molecules: Comparison of Manufacturing Process
  • Figure 11.1. Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Figure 11.2. Survey Insights: Distribution of Respondents by Company Size
  • Figure 11.3. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
  • Figure 11.4. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Figure 11.5. Survey Insights: Distribution by Designation and Seniority Level of Respondents
  • Figure 11.6. Survey Insights: Distribution by Drug Discovery Steps
  • Figure 11.7. Survey Insights: Distribution by Type of Large Molecule
  • Figure 11.8. Survey Insights: Distribution by In Silico-based Service Portfolio
  • Figure 11.9. Survey Insights: Distribution by Likely Adoption of In Silico Tools
  • Figure 11.10. Survey Insights: Distribution by Current Market Opportunity
  • Figure 11.11. Survey Insights: Distribution by Likely Growth Rate
  • Figure 11.12. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
  • Figure 12.1. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery: Growth Scenarios
  • Figure 12.2. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030 (USD Billion)
  • Figure 13.1. In Silico Drug Discovery Services Market for Large Molecules: Methodology and Key Assumptions
  • Figure 13.2. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030 (USD Million)
  • Figure 13.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020 and 2030 (USD Million)
  • Figure 13.4. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, 2020-2030 (USD Million)
  • Figure 13.5. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, 2020-2030 (USD Million)
  • Figure 13.6. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, 2020-2030 (USD Million)
  • Figure 13.7. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, 2020-2030 (USD Million)
  • Figure 13.8. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, 2020-2030 (USD Million)
  • Figure 13.9. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020 and 2030 (USD Million)
  • Figure 13.10. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, 2020-2030 (USD Million)
  • Figure 13.11. In Silico Drug Discovery Services Market for Large Molecules for Proteins, 2020-2030 (USD Million)
  • Figure 13.12. In Silico Drug Discovery Services Market for Large Molecules for Peptides, 2020-2030 (USD Million)
  • Figure 13.13. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, 2020-2030 (USD Million)
  • Figure 13.14. In Silico Drug Discovery Services Market for Large Molecules for Vectors, 2020-2030 (USD Million)
  • Figure 13.15. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020 and 2030 (USD Million)
  • Figure 13.16. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, 2020-2030 (USD Million)
  • Figure 13.17. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, 2020-2030 (USD Million)
  • Figure 13.18. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, 2020-2030 (USD Million)
  • Figure 13.19. In Silico Drug Discovery Services Market for Large Molecules: Market Attractiveness Analysis by Type of Therapeutic Area, 2020 and 2030 (USD Million)
  • Figure 13.20. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, 2020-2030 (USD Million)
  • Figure 13.21. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, 2020-2030 (USD Million)
  • Figure 13.22. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, 2020-2030 (USD Million)
  • Figure 13.23. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, 2020-2030 (USD Million)
  • Figure 13.24. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, 2020-2030 (USD Million)
  • Figure 13.25. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, 2020-2030 (USD Million)
  • Figure 13.26. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, 2020-2030 (USD Million)
  • Figure 13.27. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, 2020-2030 (USD Million)
  • Figure 13.28. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, 2020-2030 (USD Million)
  • Figure 13.29. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, 2020-2030 (USD Million)
  • Figure 13.30. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, 2020-2030 (USD Million)
  • Figure 13.31. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, 2020-2030 (USD Million)
  • Figure 13.32. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, 2020-2030 (USD Million)
  • Figure 13.33. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, 2020-2030 (USD Million)
  • Figure 13.34. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, 2020-2030 (USD Million)
  • Figure 13.35. In Silico Drug Discovery Services Market for Large Molecules for Others, 2020-2030 (USD Million)
  • Figure 13.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020 and 2030 (USD Million)
  • Figure 13.37. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, 2020-2030 (USD Million)
  • Figure 13.38. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, 2020-2030 (USD Million)
  • Figure 13.39. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020 and 2030 (USD Million)
  • Figure 13.40. In Silico Drug Discovery Services Market for Large Molecules in North America, 2020 and 2030 (USD Million)
  • Figure 13.41. In Silico Drug Discovery Services Market for Large Molecules in the US, 2020- 2030 (USD Million)
  • Figure 13.42. In Silico Drug Discovery Services Market for Large Molecules in Canada, 2020-2030 (USD Million)
  • Figure 13.43. In Silico Drug Discovery Services Market for Large Molecules in Europe, 2020 and 2030 (USD Million)
  • Figure 13.44. In Silico Drug Discovery Services Market for Large Molecules in Germany, 2020-2030 (USD Million)
  • Figure 13.45. In Silico Drug Discovery Services Market for Large Molecules in France, 2020-2030 (USD Million)
  • Figure 13.46. In Silico Drug Discovery Services Market for Large Molecules in the UK, 2020-2030 (USD Million)
  • Figure 13.47. In Silico Drug Discovery Services Market for Large Molecules in Italy, 2020-2030 (USD Million)
  • Figure 13.48. In Silico Drug Discovery Services Market for Large Molecules in Spain, 2020-2030 (USD Million)
  • Figure 13.49. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, 2020-2030 (USD Million)
  • Figure 13.50. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World, 2020 and 2030 (USD Million)
  • Figure 13.51. In Silico Drug Discovery Services Market for Large Molecules in China, 2020-2030 (USD Million)
  • Figure 13.52. In Silico Drug Discovery Services Market for Large Molecules in India, 2020-2030 (USD Million)
  • Figure 13.53. In Silico Drug Discovery Services Market for Large Molecules in Japan, 2020-2030 (USD Million)
  • Figure 14.1. Upcoming Trends in Drug Discovery: Future Growth Opportunities

List Of Tables

  • Table 4.1. In Silico Drug Discovery Service Providers for Large Molecules: List of Industry Players
  • Table 4.2. In Silico Drug Discovery Services for Large Molecules: Information on Drug Discovery Steps
  • Table 4.3. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of In Silico Approach
  • Table 4.4. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of Clienetle
  • Table 4.5. In Silico Drug Discovery Services for Large Molecules: Information on Type of Large Molecule
  • Table 4.6. In Silico Drug Discovery Services for Large Molecules: Information on In Silico-based Service Offerings
  • Table 4.7. In Silico Drug Discovery Services for Large Molecules: Additional Information
  • Table 4.8. In Silico Drug Discovery Services: List of Software / Technologies
  • Table 4.9. In Silico Drug Discovery Services: List of Consulting and Training Service Providers
  • Table 6.1. In Silico Service Providers: List of Companies Profiled
  • Table 6.2. BioDuro: Key Highlights
  • Table 6.3. BioDuro: List of Funding Instances and Investors
  • Table 6.4. BioDuro: Recent Developments and Future Outlook
  • Table 6.5. Creative Biostructure: Key Highlights
  • Table 6.6. Creative Biostructure: List of Funding Instances and Investors
  • Table 6.7. Creative Biostructure: Recent Developments and Future Outlook
  • Table 6.8. GenScript: Key Highlights
  • Table 6.9. GenScript: List of Funding Instances and Investors
  • Table 6.10. GenScript: Recent Developments and Future Outlook
  • Table 6.11. LakePharma: Key Highlights
  • Table 6.12. LakePharma: List of Funding Instances and Investors
  • Table 6.13. LakePharma: Recent Developments and Future Outlook
  • Table 6.14. Abzena: Key Highlights
  • Table 6.15. Abzena: List of Funding Instances and Investors
  • Table 6.16. Abzena: Recent Developments and Future Outlook
  • Table 6.17. BioNTech: Key Highlights
  • Table 6.18. BioNTech: List of Funding Instances and Investors
  • Table 6.19. BioNTech: Recent Developments and Future Outlook
  • Table 6.20. Sygnature Discovery: Key Highlights
  • Table 6.21. Sygnature Discovery: List of Funding Instances and Investors
  • Table 6.22. Sygnature Discovery: Recent Developments and Future Outlook
  • Table 6.23. ChemPartner: Key Highlights
  • Table 6.24. ChemPartner: Recent Developments and Future Outlook
  • Table 6.25. Sundia MediTech: Key Highlights
  • Table 6.26. Sundia MediTech: List of Funding Instances and Investors
  • Table 6.27. Sundia MediTech: Recent Developments and Future Outlook
  • Table 6.28. Viva Biotech: Key Highlights
  • Table 6.29. Viva Biotech: List of Funding Instances and Investors
  • Table 6.30. Viva Biotech: Recent Developments and Future Outlook
  • Table 10.1. Comparison of Strengths and Weaknesses of Small Molecules and Large Molecules
  • Table 10.2. Comparison of Development Characteristics of Small Molecules and Large Molecules
  • Table 10.3. Challenges in the Discovery of Different Types of Large Molecules
  • Table 11.1. Survey Insights: Overview of Respondents
  • Table 11.2. Survey Insights: Designation and Seniority Levels
  • Table 11.3. Survey Insights: Distribution by Drug Discovery Steps
  • Table 11.4. Survey Insights: Distribution by Type of Large Molecule
  • Table 11.5. Survey Insights: Distribution by In Silico-based Service Portfolio
  • Table 11.6. Survey Insights: Distribution by Likely Adoption of In Silico Tools
  • Table 11.7. Survey Insights: Distribution by Current Market Opportunity
  • Table 11.8. Survey Insights: Distribution by Likely Growth Rate
  • Table 11.9. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
  • Table 12.1. Likely Cost Reduction using In Silico Services for Large Molecules
  • Table 12.2. Drug Discovery Steps: Key Parameters
  • Table 14.1. Companies Offering Artificial Intelligence and In Silico Services
  • Table 14.2. Companies Offering Cloud Computing Platforms and In Silico Services
  • Table 15.1. Conifer Point Pharmaceuticals: Company Snapshot
  • Table 15.2. candidum: Company Snapshot
  • Table 15.3. Evotec: Company Snapshot
  • Table 15.4. ProSciens: Company Snapshot
  • Table 16.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
  • Table 16.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
  • Table 16.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
  • Table 16.4. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
  • Table 16.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
  • Table 16.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
  • Table 16.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
  • Table 16.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
  • Table 16.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Designing Approach Used
  • Table 16.10. In Silico Drug Discovery Services for Large Molecules: Distribution by In Silico Service Offering
  • Table 16.11. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005 - 2019)
  • Table 16.12. Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Table 16.13. Survey Insights: Distribution of Respondents by Employee Size
  • Table 16.14. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
  • Table 16.15. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Table 16.16. Survey Insights: Distribution by Designation and Seniority Level of Respondents
  • Table 16.17. Survey Insights: Distribution by Drug Discovery Steps
  • Table 16.18. Survey Insights: Distribution by Type of Large Molecule
  • Table 16.19. Survey Insights: Distribution by In Silico-based Service Portfolio
  • Table 16.20. Survey Insights: Distribution by Likely Adoption of In Silico Tools
  • Table 16.21. Survey Insights: Distribution by Current Market Opportunity
  • Table 16.22. Survey Insights: Distribution by Likely Growth Rate
  • Table 16.23. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
  • Table 16.24. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030 (USD Billion)
  • Table 16.25. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030 (USD Million)
  • Table 16.26. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020 and 2030 (USD Million)
  • Table 16.27. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, 2020-2030 (USD Million)
  • Table 16.28. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, 2020-2030 (USD Million)
  • Table 16.29. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, 2020-2030 (USD Million)
  • Table 16.30. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead,- 2020-2030 (USD Million)
  • Table 16.31. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, 2020-2030 (USD Million)
  • Table 16.32. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020 and 2030 (USD Million)
  • Table 16.33. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, 2020-2030 (USD Million)
  • Table 16.34. In Silico Drug Discovery Services Market for Large Molecules for Proteins, 2020-2030 (USD Million)
  • Table 16.35. In Silico Drug Discovery Services Market for Large Molecules for Peptides, 2020-2030 (USD Million)
  • Table 16.36. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, 2020-2030 (USD Million)
  • Table 16.37. In Silico Drug Discovery Services Market for Large Molecules for Vectors, 2020-2030 (USD Million)
  • Table 16.38. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020 and 2030 (USD Million)
  • Table 16.39. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, 2020-2030 (USD Million)
  • Table 16.40. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, 2020-2030 (USD Million)
  • Table 16.41. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, 2020-2030 (USD Million)
  • Table 16.42. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, 2020-2030 (USD Million)
  • Table 16.43. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, 2020-2030 (USD Million)
  • Table 16.44. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, 2020-2030 (USD Million)
  • Table 16.45. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, 2020-2030 (USD Million)
  • Table 16.46. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, 2020-2030 (USD Million)
  • Table 16.47. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, 2020-2030 (USD Million)
  • Table 16.48. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, 2020-2030 (USD Million)
  • Table 16.49. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, 2020-2030 (USD Million)
  • Table 16.50. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, 2020-2030 (USD Million)
  • Table 16.51. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, 2020-2030 (USD Million)
  • Table 16.52. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, 2020-2030 (USD Million)
  • Table 16.53. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, 2020-2030 (USD Million)
  • Table 16.54. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, 2020-2030 (USD Million)
  • Table 16.55. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, 2020-2030 (USD Million)
  • Table 16.56. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, 2020-2030 (USD Million)
  • Table 16.57. In Silico Drug Discovery Services Market for Large Molecules for Others, 2020-2030 (USD Million)
  • Table 16.58. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020 and 2030 (USD Million)
  • Table 16.59. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, 2020-2030 (USD Million)
  • Table 16.60. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, 2020-2030 (USD Million)
  • Table 16.61. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020 and 2030 (USD Million)
  • Table 16.62. In Silico Drug Discovery Services Market for Large Molecules in North America, 2020 and 2030 (USD Million)
  • Table 16.63. In Silico Drug Discovery Services Market for Large Molecules in the US, 2020- 2030 (USD Million)
  • Table 16.64. In Silico Drug Discovery Services Market for Large Molecules in Canada, 2020-2030 (USD Million)
  • Table 16.65. In Silico Drug Discovery Services Market for Large Molecules in Europe, 2020 and 2030 (USD Million)
  • Table 16.66. In Silico Drug Discovery Services Market for Large Molecules in Germany, 2020-2030 (USD Million)
  • Table 16.67. In Silico Drug Discovery Services Market for Large Molecules in France, 2020-2030 (USD Million)
  • Table 16.68. In Silico Drug Discovery Services Market for Large Molecules in the UK, 2020-2030 (USD Million)
  • Table 16.69. In Silico Drug Discovery Services Market for Large Molecules in Italy, 2020-2030 (USD Million)
  • Table 16.70. In Silico Drug Discovery Services Market for Large Molecules in Spain, 2020-2030 (USD Million)
  • Table 16.71. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, 2020-2030 (USD Million)
  • Table 16.72. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World, 2020 and 2030 (USD Million)
  • Table 16.73. In Silico Drug Discovery Services Market for Large Molecules in China, 2020-2030 (USD Million)
  • Table 16.74. In Silico Drug Discovery Services Market for Large Molecules in India, 2020-2030 (USD Million)
  • Table 16.75. In Silico Drug Discovery Services Market for Large Molecules in Japan, 2020-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 16S Technologies
  • 2. Ab Studio
  • 3. AbbVie
  • 4. AbCheck
  • 5. Abzena
  • 6. Adagio Pharmaceuticals
  • 7. Adimab
  • 8. Advent International
  • 9. Ajinomoto Bio-Pharma
  • 10. Allesh Biosciences Labs
  • 11. Allosterix Pharmaceuticals
  • 12. Ambrx
  • 13. AMRI
  • 14. Antitope (acquired by Abzena)
  • 15. Antiverse
  • 16. ApconiX
  • 17. Aprecia Pharmaceuticals
  • 18. Aptuit
  • 19. AsiaVest Partners
  • 20. AstraZeneca
  • 21. ATHOS Service
  • 22. Avistron Chemistry Services
  • 23. Bayer Animal Health
  • 24. BDG LifeSciences
  • 25. BenevolentAI
  • 26. Berkeley Lights
  • 27. Betta Biomedical Industry Fund
  • 28. BIANA
  • 29. Bill & Melinda Gates Foundation
  • 30. BioAscent
  • 31. BioBench Solutions
  • 32. Bioclinica
  • 33. BioDuro
  • 34. BioGlobal Consulting Group
  • 35. BioNTech
  • 36. Biotech Investment Group
  • 37. BIOTEM
  • 38. BMG LABTECH
  • 39. Broad Institute of MIT and Harvard
  • 40. BVCF Management
  • 41. Caldan Therapeutics
  • 42. CALIXAR
  • 43. candidum
  • 44. CardioVascular Research Foundation
  • 45. CARLBio
  • 46. Catalent Pharma Solutions
  • 47. CELLSCRIPT
  • 48. Charles River Laboratories
  • 49. ChemBio Discovery Solutions
  • 50. ChemBridge
  • 51. ChemDiv
  • 52. ChemoGenics BioPharma
  • 53. ChemPartner
  • 54. Cloud Pharmaceuticals
  • 55. CompChem Solutions
  • 56. Concept Life Sciences
  • 57. Conifer Point
  • 58. Conifer Point Pharmaceuticals
  • 59. Creative Biolabs
  • 60. Creative Biostructure
  • 61. Creative Diagnostics
  • 62. Cyclica
  • 63. Cyprotex
  • 64. Defense Advanced Research Projects Agency
  • 65. Domainex
  • 66. DuPont
  • 67. Eli Lilly
  • 68. European Investment Bank
  • 69. Evotec
  • 70. Fidelity Management & Research
  • 71. Fidelta (a CRO Subsidiary of Galapagos)
  • 72. Formex
  • 73. Fractal Therapeutics
  • 74. Fusion Antibodies
  • 75. Genedata Biologics
  • 76. Genentech
  • 77. Genevant Sciences
  • 78. Genmab
  • 79. Genomodel
  • 80. GenScript
  • 81. Gfree Bio
  • 82. Greenpharma
  • 83. Harlan Laboratories
  • 84. Harvard University
  • 85. HiFiBiO
  • 86. HQL Pharmaceuticals
  • 87. IBM Watson
  • 88. Icagen
  • 89. ICON
  • 90. IDG Capital
  • 91. ImmunoPrecise Antibodies
  • 92. In-Cell-Art
  • 93. Insilico Medicine
  • 94. Inte:Ligand
  • 95. Integral Molecular
  • 96. Invus
  • 97. IRBM
  • 98. Ironwood Pharmaceuticals
  • 99. IXTAL
  • 100. Janssen
  • 101. Janus Henderson Investors
  • 102. Jebsen Capital
  • 103. JPT Peptide Technologies
  • 104. Jubilant Biosys
  • 105. Keapstone Therapeutics
  • 106. LakePharma
  • 107. Lead Discovery Center
  • 108. LeadInvent Technologies
  • 109. Life Technologies
  • 110. MabVax Therapeutics
  • 111. Mascot Industries
  • 112. Merck
  • 113. Metropolis Healthcare
  • 114. Micar Innovation
  • 115. MIG Funds
  • 116. Mind the Byte
  • 117. Mirae Asset
  • 118. Molecular Devices
  • 119. Molecular Forecaster
  • 120. Molecular Response
  • 121. Moleculomics
  • 122. Molsoft
  • 123. N2 Business Growth Fund
  • 124. NIH
  • 125. NovaData Solutions
  • 126. NovAliX
  • 127. Novartis
  • 128. Novo Informatics
  • 129. NuChem Therapeutics
  • 130. Numerate
  • 131. NYU Langone Health
  • 132. Oscotec
  • 133. PacificGMP
  • 134. Patheon
  • 135. Pathios Therapeutics
  • 136. Peak Proteins
  • 137. Pelago Bioscience
  • 138. Pepscan
  • 139. Peptone
  • 140. Pfizer
  • 141. Pharma Inventor
  • 142. Pharmacelera
  • 143. Pharmacia
  • 144. Phoenix Equity Partners
  • 145. Platinum Asset Management
  • 146. PolyTherics (acquired by Abzena)
  • 147. Porton Pharma Solutions
  • 148. PPD
  • 149. Prestwick Chemical (acquired by Bionomics)
  • 150. Profacgen
  • 151. ProMab Biotechnologies
  • 152. Prosarix
  • 153. ProteinQure
  • 154. ProteoGenix
  • 155. Provid Pharmaceuticals
  • 156. PX'Therapeutics
  • 157. QIAGEN
  • 158. Quantitative Medicine
  • 159. RASA Life Science Informatics
  • 160. Redmile Group
  • 161. RedX Pharma
  • 162. Roche
  • 163. Rosa
  • 164. Rosetta Design Group
  • 165. RuiYi
  • 166. Sai Life Sciences
  • 167. Sandexis
  • 168. Sandoz
  • 169. Sanofi
  • 170. Schering Plough
  • 171. Schrödinger
  • 172. Shuwen Biotech
  • 173. SilcsBio
  • 174. Sitryx
  • 175. Sonnet BioTherapeutics
  • 176. Sosei Heptares
  • 177. Steam Athena Capital
  • 178. Struengmann Family Office
  • 179. Sundia MediTech
  • 180. Sygnature Discovery
  • 181. Syngene
  • 182. Taros Chemicals
  • 183. Telix Pharmaceuticals
  • 184. The Chemistry Research Solution (acquired by Abzena)
  • 185. Tmunity Therapeutics
  • 186. TRIANNI
  • 187. University of Pennsylvania
  • 188. UPM
  • 189. Viramatix
  • 190. Virtua Drug
  • 191. Viva Biotech
  • 192. Viva Vision
  • 193. Warwick Effect Polymers
  • 194. WuXi AppTec
  • 195. Wyss Institute
  • 196. YUMAB
  • 197. ZoBio
  • 198. Zorilla Research